Cargando…
Cancer Pain Management: Opioid Analgesics, Part 2
Opioid analgesics are the cornerstone of moderate to severe cancer pain management, and do not have ceiling doses unless unmanageable adverse effects occur. Oral, short-acting pure μ agonists such as morphine are most frequently used, but other agents and administration formulations allow finding th...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167083/ https://www.ncbi.nlm.nih.gov/pubmed/30310721 |
_version_ | 1783360141890945024 |
---|---|
author | Wickham, Rita J. |
author_facet | Wickham, Rita J. |
author_sort | Wickham, Rita J. |
collection | PubMed |
description | Opioid analgesics are the cornerstone of moderate to severe cancer pain management, and do not have ceiling doses unless unmanageable adverse effects occur. Oral, short-acting pure μ agonists such as morphine are most frequently used, but other agents and administration formulations allow finding the right opioid and dose for most patients. In addition, clinicians must understand the metabolism, pharmacokinetics, and elimination of particular drugs to individualize opioid selection, select initial doses, and appropriately escalate doses to satisfactory pain relief or uncontrollable toxicity. Anticipation and proactive management of possible adverse effects, particularly constipation, confusion or delirium, opioid-specific adverse effects, and opioid abuse, are also integral to primary and secondary prophylaxis and management. |
format | Online Article Text |
id | pubmed-6167083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Harborside Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61670832018-10-11 Cancer Pain Management: Opioid Analgesics, Part 2 Wickham, Rita J. J Adv Pract Oncol Review Article Opioid analgesics are the cornerstone of moderate to severe cancer pain management, and do not have ceiling doses unless unmanageable adverse effects occur. Oral, short-acting pure μ agonists such as morphine are most frequently used, but other agents and administration formulations allow finding the right opioid and dose for most patients. In addition, clinicians must understand the metabolism, pharmacokinetics, and elimination of particular drugs to individualize opioid selection, select initial doses, and appropriately escalate doses to satisfactory pain relief or uncontrollable toxicity. Anticipation and proactive management of possible adverse effects, particularly constipation, confusion or delirium, opioid-specific adverse effects, and opioid abuse, are also integral to primary and secondary prophylaxis and management. Harborside Press 2017 2017-09-01 /pmc/articles/PMC6167083/ /pubmed/30310721 Text en Copyright © 2017, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes. |
spellingShingle | Review Article Wickham, Rita J. Cancer Pain Management: Opioid Analgesics, Part 2 |
title | Cancer Pain Management: Opioid Analgesics, Part 2 |
title_full | Cancer Pain Management: Opioid Analgesics, Part 2 |
title_fullStr | Cancer Pain Management: Opioid Analgesics, Part 2 |
title_full_unstemmed | Cancer Pain Management: Opioid Analgesics, Part 2 |
title_short | Cancer Pain Management: Opioid Analgesics, Part 2 |
title_sort | cancer pain management: opioid analgesics, part 2 |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167083/ https://www.ncbi.nlm.nih.gov/pubmed/30310721 |
work_keys_str_mv | AT wickhamritaj cancerpainmanagementopioidanalgesicspart2 |